Skip to content
10-Q

Quarterly Report

MADRIGAL PHARMACEUTICALS, INC. MDGL

0001628280-25-021356

← back to feed
Filed
May 1, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 28, 2025 22.2M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $118.01M
Long Term Debt Q1 2025 · Dec 31, 2024 $117.57M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $183.65M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $100.02M
Current Liabilities Q1 2025 · Mar 31, 2025 $167.24M
Current Liabilities Q1 2025 · Dec 31, 2024 $169.28M
Total Liabilities Q1 2025 · Mar 31, 2025 $285.99M
Total Liabilities Q1 2025 · Dec 31, 2024 $287.86M
Current Assets Q1 2025 · Mar 31, 2025 $987.98M
Current Assets Q1 2025 · Dec 31, 2024 $1.03B
Total Assets Q1 2025 · Mar 31, 2025 $996.63M
Total Assets Q1 2025 · Dec 31, 2024 $1.04B
Cost Of Revenue Q1 2025 · Mar 31, 2025 $4.51M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $0
Shares Diluted Q1 2025 · Mar 31, 2024 20M sh
Capex Q1 2025 · Mar 31, 2024 $357K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$149.16M
Stockholders Equity Q1 2025 · Mar 31, 2024 $850.76M
Stockholders Equity Q1 2025 · Dec 31, 2023 $405.33M
Eps Diluted Q1 2025 · Mar 31, 2024 −$7.38
Eps Basic Q1 2025 · Mar 31, 2024 −$7.38
Sga Expense Q1 2025 · Mar 31, 2024 $80.8M
Net Income Q1 2025 · Mar 31, 2024 −$147.54M
Operating Income Q1 2025 · Mar 31, 2024 −$152.04M
Revenue Q1 2025 · Mar 31, 2024 $0